July 16th 2025
Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.
AAO Reacts to Ranibizumab Biosimilar Approval
September 23rd 2021The Center for Biosimilars® spoke with George Williams, MD, clinical spokesperson for the American Academy of Ophthalmology (AAO), about the FDA’s recent approval of Byooviz (ranibizumab), the first biosimilar specifically approved for treatment of eye diseases.
Axinn’s Landmon Provides an Expert Legal Opinion on HHS’ Drug Price Strategy
September 22nd 2021The HHS plan ordered up by President Biden for combatting high drug prices is a hodgepodge of ideas that have long circulated in Washington, DC, but can any of them be made to stick? An intellectual property and FDA policy expert, Chad Landmon, JD, shares his perspective.
Not So Different: How Biosimilar Companies Are Stepping Up Their Game to Compete Against Originators
September 19th 2021Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, discusses some of the tactics that biosimilar companies are employing in order to level the playing field and better compete against originator companies.
Chad Pettit, MBA, Discusses Amgen’s Biosimilar Trends Report and the Future of Biosimilars in the US
August 18th 2021Chad Pettit, MBA, executive director of Marketing and the Global Biosimilars commercial lead for Amgen, discussed the company’s 2021 Biosimilar Trends Report and his projections for the future of the biosimilars market.
Neal Dave, PharmD, Discusses What Clinics Need to Do to Ensure Biosimilars Are Cost-efficient
August 9th 2021Health care systems need to consistently reevaluate whether the biosimilars they utilize are the most cost-effective, Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, explains.
Not So Different: What the Generics Industry Can Tell Us About the Future of Biosimilars
July 18th 2021On this week’s episode of Not So Different, we spoke with David Senior, senior vice president of Market Economics at AmerisourceBergen, about the development of the generics market and how this could be instructive in understanding how biosimilars sales may develop.
Not So Different: How Henlius is Making Its Mark on the Global Biosimilar Industry
June 20th 2021Ping Cao, vice president of Business Development for Shanghai Henlius Biotech, discussed the company's current biosimilar development plans and the process for getting regulatory approval for biosimilars in China.